RxDoctor Payments Data

Muzibul Chowdhury, MD

Internal Medicine · Windsor, CTNPI 1093730012

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 41 payments — averaging $36.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arbor Pharmaceuticals, Inc.$413
  • Novartis$235
  • Novo Nordisk$232
  • Johnson & Johnson$229
  • Amarin Pharma, Inc.$124
  • AstraZeneca$113
  • plus $145 from 5 others

What the payments were for

  • Food & beverage$1,47099%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,492 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$27,800
Medicare patients
121
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$135,930
EliquisApixaban70$86,354
XareltoRivaroxaban31$38,994
TrulicityDulaglutide18$38,042
OzempicSemaglutide31$37,770
FarxigaDapagliflozin Propanediol14$21,894
JanuviaSitagliptin Phosphate16$20,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,063
EdarbiAzilsartan Medoxomil11$5,794
Rosuvastatin Calcium408$5,573
SynthroidLevothyroxine Sodium42$4,654
Olmesartan Medoxomil188$3,894
Niacin ErNiacin34$3,469
SymbicortBudesonide/Formoterol Fumarate12$3,299
Humalog Kwikpen U-100Insulin Lispro14$3,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$229$38,99431 claims
Novo NordiskOzempic$232$37,77031 claims
AstraZenecaFarxiga, Symbicort$113$25,19226 claims
MerckJanuvia$22$20,90116 claims
Arbor Pharmaceuticals, Inc.Edarbi$413$5,79411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →